Modernizing Medicare Part D

Key Resources (listed chronologically, beginning with the most recent)

“How Will the Medicare Part D Benefit Change Under Current Law and Leading Proposals.” Cubanski, J. and Neuman, T. Kaiser Family Foundation. October 11, 2019. Available at

“Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2019 Year-End Update.” Schondelmeyer, S. and Purvis, L. AARP Public Policy Institute. September 2019. Available at

“Competing Proposals to Reform Medicare Part D.” Hayes, T. American Action Forum. September 23, 2019. Available at

“What’s the Latest on Medicare Drug Price Negotiations?” Cubanski, J., Neuman, T., True, S., et al. Kaiser Family Foundation. July 23, 2019. Available at

“10 Things to Know About Medicare Part D Coverage and Costs in 2019.” Cubanski, J., Damico, A., Neuman, T. Kaiser Family Foundation. June 4. 2019. Available

“Effect of Potential Policy Change to Part D Generic Tiering on Patient Cost Sharing and Part D Plan Costs.” Sloan, C. McDonald, R., Young, J., et al. Avalere. February 28, 2019. Available at

“Redesigning Medicare Part D to Realign Incentives.” Hayes, T. American Action Forum. August 14, 2018. Available at

“Medicare Part D Improvements Help Beneficiaries and Taxpayers.” Purvis, L. AARP Public Policy Institute. July 9, 2018. Available at

Additional Resources (listed chronologically, beginning with the most recent)

“The Drug Pricing Clinic.” Holt, C., Hayes, T., Couture, B., et. al. American Action Forum. September 26, 2019. Available at

“Medicare Price Negotiation—Why Now…and How.” Frank, R. and Nichols, L. The New England Journal of Medicine. September 4, 2019. Available at

“37.4M Part D Beneficiaries are Projected to Reach the Catastrophic Phase in 2020.” Avalere. August 28, 2019. Available at

“The Economics of Biologic Drugs.” Brill, A. and Ippolito, B. Health Affairs Blog. August 8, 2019. Available at

“Senate Finance Committee Proposes Reforms to Medicare and Medicaid Drug Policy.” Hayes, T. American Action Forum. August 6, 2019. Available at

“Evaluating the Senate Finance Committee Proposal to Restructure Medicare Part D.” Gottlieb, S. AEIdeas. July 24, 2019. Available at

“With Rebates off the Table, What’s Next for Drug Pricing and Regulation?” Thomas, S. Deloitte. July 23, 2019. Available at

“Setting the Record Straight on International Reference Pricing.” Haninger, K. The Catalyst (blog). Pharmaceutical Research and Manufacturers of America. July 16, 2019. Available at

“Sending the Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less than Generics?” Dusetzina, S., Jazowski, S., Cole, A., et al. Health Affairs. July 2, 2019. Available at

“Reconciling the Seemingly Irreconcilable: How Much are We Spending on Drugs?” Kleinrock, M., Westrich, K., Buelt, L., et al. IQVIA Institute for Human Data Science and The National Pharmaceutical Council. July 2019. Available at

“Medicare Part D: Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization.” GAO Highlights. July 2019. Available at

“How Drug Prices are Negotiated in Germany.” Robinson, J., Ex, P., and Panteli, D. To the Point (blog). The Commonwealth Fund. June 13, 2019. Available at

“Capping Seniors’ Out-of-Pocket Prescription Drug Costs Could Increase Medicare Prices– and Premiums.” Forbes. June 11, 2019. Available at

“Six Drug Pricing Models Have Emerged to Improve Product Access and Affordability.” Comer, B. PwC. May 29, 2019. Available at

“Is Arbitration an Answer for High Drug Prices?” Rother J. To the Point (blog). The Commonwealth Fund. May 3, 2019. Available at

“A Closer Look at International Reference Pricing for Prescription Drugs.” Capretta, J. RealClearPolicy. March 29, 2019. Available at

“Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid.” Congressional Budget Office. March 2019. Available at

“What Medicare Can Learn from Other Countries on Drug Pricing” Roy, A. The Foundation for Research on Equal Opportunity. January 11, 2019. Available at

“Proposed Changes to Medicare D Would Benefit Drug Manufacturers More than Beneficiaries.” Bishop, S. January 2, 2019. Available at

“Balancing Innovation and Competition in the Biologics Marketplace.” Korn, D. The Catalyst (blog).  Pharmaceutical Research and Manufacturers of America. October 11, 2018. Available at

“Rising Costs for Patented Drugs Drive Growth of Pharmaceutical Spending in the U.S.” Blue Cross Blue Shield. The Health of America Report. May 3, 2017. Available at

“Fact Sheet: How Much Money Could Medicare Save By Negotiating Prescription Drug Prices?” Committee for a Responsible Federal Budget. April 11, 2016. Available at

“Point of Sale Rebate Analysis in the Commercial Market: Sharing Rebates May Lower Patient Costs and Likely has Minimal Impact on Premiums.” Bunger, A., Gomberg, J., Hunter, M., et. al. Milliman and PhRMA. October 2017. Available at